Positioning and classification of enteral nutrition products with sedative effects
DOI:
https://doi.org/10.31617/2.2025(56)04Keywords:
Cannabidiol, enteral nutrition, commodity classification, standardization, quality control.Abstract
The integration of cannabidiol into enteral nutrition products creates a new scientific, technological, and regulatory challenge, as the development of such products does not fit into traditional commodity classification paradigms. The lack of unambiguous regulatory and commercial identification creates a legal vacuum and complicates the development of effective quality control and standardization methods. A scientific and practical hypothesis is substantiated: effective commodity identification and quality control of enteral nutrition products containing cannabidiol cannot be ensured within the current regulatory framework, but will become possible upon the development and implementation of a scientifically grounded two-tier classification model that takes into account both the medical purpose of the product and its physicochemical stability. The research is based on systematic literature review methods and the analysis of national and international regulatory documents. It is established that product quality is determined by the synergy of raw material characteristics (isolate, extract), formulation technology, and storage/packaging conditions. Regulatory analysis indicates significant fragmentation: the European Food Safety Authority (EFSA) noted data gaps in the assessment of CBD as a "Novel Food," while in Ukraine, conditions have been established for the legal circulation of cannabidiol extracts, requiring harmonization with technical regulations. The necessity of using highly sensitive liquid chromatography with a mass spectrometric detector for the selective identification of cannabidiol and the control of accompanying cannabinoids is substantiated. A multi-dimensional approach to classification is proposed, which is critically important for developing internal technical regulations, labeling rules, and customs tariff classification.
References
Commission Recommendation (EU) 2016/2115 of 1 December 2016 on the monitoring of the presence of Δ9-tetrahydrocannabinol, its precursors and other cannabinoids in food and feed. (2016). Official Journal of the European Union, L 329, 87-93. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32016H2115
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018). Translational investigation of the therapeutic potential of cannabidiol (CBD): Toward a new age. Frontiers in Immunology, 9, 2009. https://doi.org/10.3389/fimmu.2018.02009
EUR-Lex. (2020, November 19). Judgment of the Court (Fourth Chamber) of 19 November 2020, Criminal proceedings against B S and C A, Case C 663/18 (Document 62018CJ0663). European Union. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:62018CJ0663
European Parliament and Council of the European Union. (2015). Regulation
(EU) 2015/2283 on novel foods. Official Journal of the European Union. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32015R228
FDA. U.S. Food and Drug Administration. (2023). FDA regulation of cannabis and cannabis-derived products, including cannabidiol (CBD). https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
Hampson, A. J., & Riba, S. A. (2022). The regulation of cannabidiol (CBD) in the European Union. Journal of Dietary Supplements, 19(5), 515-534. https://pubmed.ncbi.nlm.nih.gov/34341908/
Malaca, S., Gottardi, M., Pigliasco, F., Barco, S., Cafaro, A., Amadori, E., Minassi, A., Taglialatela-Scafati, O., Perucca, E., Carabellese, N., Toffoli, G., Zancanaro, C., Leone, G., Simonetti, G., Chiarotti, F., & Busardò, F. P. (2021). UHPLC-MS/MS analysis of cannabidiol and its metabolites in serum of patients with resistant epilepsy treated with CBD formulations. Pharmaceuticals, 14(7), 630. https://doi.org/10.3390/ph14070630
Prytulska, N., Antiushko, D., Ladyka, V., & Samilyk, M. (2024). Food production: Innovative technological solutions. Technology Center PC. https://doi.org/10.15587/978-617-7319-99-2
Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety. (2002, January 28). Official Journal of the European Union, L 31, 1-24. https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A32002R0178
Taha, I. E., ElSohly, M. A., Radwan, M. M., Elkanayati, R. M., Wanas, A., Joshi, P. H., & Ashour, E. A. (2025). Enhancement of cannabidiol oral bioavailability through the development of nanostructured lipid carriers: In vitro and in vivo evaluation studies. Drug Delivery and Translational Research, 15(8), 2722-2732. https://doi.org/10.1007/s13346-024-01766-9
Tavčar, E., & Vidak, M. (2024). Experimental investigation and thermodynamic modelling of cannabidiol and curcumin in different solvents. Journal of molecular liquids, 410, 125511. https://doi.org/10.1016/j.molliq.2024.125511
Turck, D., Bohn, T., Cámara, M., Castenmiller, J., De Henauw, S., Jos, Á., Maciuk, A., Mangelsdorf, I., McNulty, B., Naska, A., Pentieva, K., Siani, A., Thies, F., Aguilera-Gómez, M., Cubadda, F., Marchelli, R., McArdle, H. J., Moldeus, P., … Hirsch-Ernst, K. I. (2015). Safety of synthetic cannabidiol as a novel food pursuant to Regulation
(EU) 2015/2283. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). EFSA Journal, 23(1), Article e09708. https://doi.org/10.2903/j.efsa.2025.9708
Turck, D., Bohn, T., Castenmiller, J., De Henauw, S., Hirsch‐Ernst, K. I., & Knutsen, H. K. (2022). Statement on safety of cannabidiol as a novel food: Data gaps and uncertainties. EFSA Journal, 20(6), e07322. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). https://doi.org/10.2903/j.efsa.2022.7322
Zhang, Q., Huo, Yu., Yang, Q., Zhao, F., Li, M., & Ju, J. (2025). Migration of chemical substances from packaging materials to food. Food Chemistry, 455, 144544. https://pubmed.ncbi.nlm.nih.gov/40311566/; https://doi.org/10.1016/j.foodchem.2025.144544
Lajko, I. M., Mishchenko, S. V., Orlov, M. M., Marynchenko, I. O., Shkurdoda, S. V., & Pasichnyk, V. V. (2015). Prospects for reorienting cannabis breeding to create varieties for medical use. Scientific papers of the Institute of Bioenergy Crops and Sugar Beet, (23), 107-111.
Resolution of the Cabinet of Ministers of Ukraine "On Amendments to the List of Narcotic Drugs, Psychotropic Substances and Precursors" No. 653 (2024, May 24). https://zakon.rada.gov.ua/laws/show/653-2024-%D0%BF#Text
Khaitovych, M. V., & Misiura, O. M. (2025). Efficacy and safety of cannabinoid use in patients with neuropathic pain (a literature review). https://doi.org/10.32345/2664-4738.1.2025.19
